HLS Therapeutics Inc T.HLS

Alternate Symbol(s): HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.

TSX:HLS - Post by User

HLS Therapeutics Inc

Bullboard Posts

Comment by StompinTomon Mar 05, 2015 2:54pm

185 Views

Post# 23494647

RE:News

Some quick notes:

- staff level of under 10 means you are likely keeping on CEO, CFO, BD, HR?, Facility guy to ensure full decommisioning, legal to handle GM Lawsuit, someone for finance, Ops guy with experience to run an acquired company. My bet is your running costs for salaries are then maybe $300K/quarter for staff, some for legal/investment bankers
- financials will show cash status as well as if the decommissioning provision was accurate
- the wording is very shareholder friendly
- good final Q as well

Bullboard Posts

Visionstate set to leverage success in the U.S. market